title: Beneficial effect of agmatine on brain apoptosis, astrogliosis, and edema after rat transient cerebral ischemia.
abstract: BACKGROUND
  Although agmatine therapy in a mouse model of transient focal cerebral ischemia is highly protective against neurological injury, the mechanisms underlying the protective effects of agmatine are not fully elucidated. This study aimed to investigate the effects of agmatine on brain apoptosis, astrogliosis and edema in the rats with transient cerebral ischemia.
  
  
  METHODS
  Following surgical induction of middle cerebral artery occlusion (MCAO) for 90 min, agmatine (100 mg/kg, i.p.) was injected 5 min after beginning of reperfusion and again once daily for the next 3 post-operative days. Four days after reperfusion, both motor and proprioception functions were assessed and then all rats were sacrificed for determination of brain infarct volume (2, 3, 5-triphenyltetrazolium chloride staining), apoptosis (TUNEL staining), edema (both cerebral water content and amounts of aquaporin-4 positive cells), gliosis (glial fibrillary acidic protein [GFAP]-positive cells), and neurotoxicity (inducible nitric oxide synthase [iNOS] expression).
  
  
  RESULTS
  The results showed that agmatine treatment was found to accelerate recovery of motor (from 55 degrees to 62 degrees) and proprioception (from 54% maximal possible effect to 10% maximal possible effect) deficits and to prevent brain infarction (from 370 mm3 to 50 mm3), gliosis (from 80 GFAP-positive cells to 30 GFAP-positive cells), edema (cerebral water contents decreased from 82.5% to 79.4%; AQP4 positive cells decreased from 140 to 84 per section), apoptosis (neuronal apoptotic cells decreased from 100 to 20 per section), and neurotoxicity (iNOS expression cells decreased from 64 to 7 per section) during MCAO ischemic injury in rats.
  
  
  CONCLUSIONS
  The data suggest that agmatine may improve outcomes of transient cerebral ischemia in rats by reducing brain apoptosis, astrogliosis and edema.
authors.affiliation: Department of Surgery, Chi Mei Medical Center, Tainan 710, Taiwan.|Department of Biotechnology, Southern Taiwan University, Tainan 710, Taiwan.
authors.forename: Che-Chuan
authors.initials: CC
authors.lastname: Wang
authors.affiliation: Department of Surgery, Chi Mei Medical Center, Tainan 710, Taiwan.
authors.forename: Chung-Ching
authors.initials: CC
authors.lastname: Chio
authors.affiliation: Department of Surgery, Chi Mei Medical Center, Tainan 710, Taiwan.
authors.forename: Ching-Hong
authors.initials: CH
authors.lastname: Chang
authors.affiliation: Department of Surgery, Chi Mei Medical Center, Tainan 710, Taiwan.|Department of Biotechnology, Southern Taiwan University, Tainan 710, Taiwan.
authors.forename: Jinn-Rung
authors.initials: JR
authors.lastname: Kuo
authors.affiliation: Department of Biotechnology, Southern Taiwan University, Tainan 710, Taiwan.|Department of Medical Research, Chi Mei Medical Center, Tainan 710, Taiwan.
authors.forename: Ching-Ping
authors.initials: CP
authors.lastname: Chang
mesh_terms: D000376:Agmatine / Q000627:therapeutic use*; D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D051401:Aquaporin 4 / Q000378:metabolism; D001253:Astrocytes / Q000187:drug effects; D015415:Biomarkers / Q000378:metabolism; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D001929:Brain Edema / Q000517:prevention & control*; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D005911:Gliosis / Q000517:prevention & control*; D020244:Infarction, Middle Cerebral Artery / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D002546:Ischemic Attack, Transient / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D008297:Male; D009069:Movement Disorders / Q000188:drug therapy / Q000517:prevention & control; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000517:prevention & control; D012678:Sensation Disorders / Q000188:drug therapy / Q000517:prevention & control; D013997:Time Factors
chemical_list: C496032:Aqp4 protein, rat; D051401:Aquaporin 4; D015415:Biomarkers; D005904:Glial Fibrillary Acidic Protein; D018696:Neuroprotective Agents; D000376:Agmatine; D052247:Nitric Oxide Synthase Type II; C496318:Nos2 protein, rat
references.citation: Exp Neurol. 2004 Sep;189(1):122-30
references.pmid: 15296842
references.citation: Brain Res Mol Brain Res. 2000 May 31;78(1-2):131-7
references.pmid: 10891592
references.citation: J Neurotrauma. 2004 May;21(5):521-39
references.pmid: 15165361
references.citation: Brain Res. 2009 Jul 24;1281:64-70
references.pmid: 19465011
references.citation: Anesthesiology. 2003 Jun;98(6):1484-90
references.pmid: 12766662
references.citation: Trends Neurosci. 1997 Mar;20(3):132-9
references.pmid: 9061868
references.citation: Br J Pharmacol. 1999 Jul;127(6):1317-26
references.pmid: 10455281
references.citation: J Neurochem. 2000 May;74(5):2201-8
references.pmid: 10800966
references.citation: Jpn J Pharmacol. 1995 Nov;69(3):285-7
references.pmid: 8699639
references.citation: Biochem J. 1996 May 15;316 ( Pt 1):247-9
references.pmid: 8645212
references.citation: Ann N Y Acad Sci. 2003 Dec;1009:20-9
references.pmid: 15028566
references.citation: Stroke. 1996 Sep;27(9):1616-22; discussion 1623
references.pmid: 8784138
references.citation: Neuroreport. 1995 Oct 2;6(14):1897-900
references.pmid: 8547593
references.citation: J Cereb Blood Flow Metab. 2005 Aug;25(8):1012-9
references.pmid: 15744246
references.citation: BMC Neurosci. 2007 Oct 02;8:81
references.pmid: 17908330
references.citation: Anesthesiology. 1995 Apr;82(4):1013-25
references.pmid: 7717536
references.citation: Glia. 2006 Jan 15;53(2):212-24
references.pmid: 16206168
references.citation: J Neurosci Methods. 2008 Feb 15;168(1):186-94
references.pmid: 17953994
references.citation: Neuroreport. 1999 Dec 16;10(18):3927-31
references.pmid: 10716235
references.citation: J Neurosci. 1997 Jun 1;17(11):4341-8
references.pmid: 9151750
references.citation: J Neurosurg Spine. 2006 May;4(5):392-9
references.pmid: 16703907
references.citation: J Cell Sci. 1995 Sep;108 ( Pt 9):2993-3002
references.pmid: 8537439
references.citation: Pain. 2003 May;103(1-2):49-55
references.pmid: 12749958
references.citation: Neurosci Lett. 2000 Dec 22;296(2-3):97-100
references.pmid: 11108990
references.citation: Glia. 2008 Apr 15;56(6):587-96
references.pmid: 18286643
references.citation: Neuroreport. 2000 Sep 28;11(14):3203-7
references.pmid: 11043549
references.citation: Brain Res. 2006 Apr 21;1084(1):210-6
references.pmid: 16546145
references.citation: Science. 1994 Sep 23;265(5180):1883-5
references.pmid: 7522345
references.citation: Nat Med. 2000 Feb;6(2):159-63
references.pmid: 10655103
references.citation: J Cereb Blood Flow Metab. 2010 May;30(5):943-9
references.pmid: 20029450
references.citation: Proc Assoc Am Physicians. 1997 Jan;109(1):51-7
references.pmid: 9010916
references.citation: Brain Res. 2000 Jul 28;872(1-2):141-8
references.pmid: 10924686
references.citation: Life Sci. 1996;58(2):PL 41-6
references.pmid: 8606618
references.citation: Eur J Neurosci. 2008 Mar;27(6):1320-32
references.pmid: 18364017
references.citation: J Neurosci Res. 2006 May 15;83(7):1231-40
references.pmid: 16511868
references.citation: Cell Mol Neurobiol. 2003 Oct;23(4-5):865-72
references.pmid: 14514037
references.citation: J Cardiovasc Pharmacol. 2008 Mar;51(3):223-30
references.pmid: 18356685
references.citation: Stroke. 1997 Jun;28(6):1283-8
references.pmid: 9183363
references.citation: J Clin Invest. 1997 Sep 1;100(5):957-62
references.pmid: 9276712
references.citation: Life Sci. 2009 Jan 2;84(1-2):28-32
references.pmid: 18992261
references.citation: J Neurosci. 1997 Jan 1;17(1):171-80
references.pmid: 8987746
references.citation: Science. 1994 Feb 18;263(5149):966-9
references.pmid: 7906055